We are live on ! Find out more
PBM

Propel Bio Management Portfolio holdings

AUM $159M
1-Year Est. Return 60.94%
This Fund
S&P 500
This Quarter Est. Return
+28.07%
1 Year Est. Return
+60.94%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$121M
AUM Growth
–
Cap. Flow
+$104M
Cap. Flow %
85.99%
Top 10 Hldgs %
71.63%
Holding
34
New
34
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PAGP icon
Plains GP Holdings
PAGP
+$21.7M
2
APLT
Applied Therapeutics
APLT
+$13.4M
3
TCRX icon
TScan Therapeutics
TCRX
+$9.55M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$5.26M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.06M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 62.69%
2 Energy 18.15%
3 Technology 2.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLQD icon
26
iShares 0-5 Year Investment Grade Corporate Bond ETF
SLQD
$2.37B
$598K 0.5%
+12,148
New +$587K
LQD icon
27
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
$34.4B
$493K 0.41%
+4,456
New +$464K
XFOR icon
28
X4 Pharmaceuticals
XFOR
$372M
$449K 0.37%
+17,833
New +$434K
HELP
29
Cybin Inc
HELP
$477M
$349K 0.29%
+22,368
New +$416K
FLRN icon
30
State Street SPDR Bloomberg Investment Grade Floating Rate ETF
FLRN
$3.07B
$283K 0.24%
+9,267
New +$284K
HRTX icon
31
Heron Therapeutics
HRTX
$86.9M
$177K 0.15%
+104,195
New +$115K
AGIO icon
32
Agios Pharmaceuticals
AGIO
$2.2B
$129K 0.11%
+5,792
New +$130K
1
2

Similar funds

OS
Objectivity Squared Charleston, South Carolina $159M AUM 22.15% 1-Year Est. Return
BDAM
Blue Door Asset Management Stamford, Connecticut $159M AUM 38.2% 1-Year Est. Return
OC
Oppenheimer & Close New York $159M AUM 60.56% 1-Year Est. Return
JF
Jericho Financial Westerville, Ohio $159M AUM 27.21% 1-Year Est. Return
1L
10Elms LLP Tulsa, Oklahoma $159M AUM 13.16% 1-Year Est. Return
USWIA
UP Strategic Wealth Investment Advisors Pittsburgh, Pennsylvania $159M AUM 24.31% 1-Year Est. Return
EWA
Elevate Wealth Advisory Athens, Georgia $158M AUM 15.64% 1-Year Est. Return
RP
RIHO Partners Tucson, Arizona $159M AUM

Propel Bio Management's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for Propel Bio Management, which disclosed 34 positions worth $121M. Its ten largest holdings account for 72% of the portfolio.

Its largest position is Plains GP Holdings: 1,372,360 shares worth $21.9M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, followed by Energy and Technology.

  • Propel Bio Management's largest Q4 2023 buy was Plains GP Holdings: 1,372,360 shares worth $21.9M.
  • Propel Bio Management's ten largest holdings make up 72% of its $121M portfolio in Q4 2023.
  • Propel Bio Management disclosed 34 positions in Q4 2023, its first 13F filing on record.

Based on Propel Bio Management's 13F filing for Q4 2023, filed 14 Feb 2024.